Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
491. |
ECCT/14/12/01 | Rivaroxaban for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) XALIA LEA- Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia |
Principal Investigator(s) 1. Anne Njeri Mugera Njambi Mugera 2. Dr. Martin N Wanyoike Njoroge Wanyoike 3. Charles Muthui Kariuki Muthui Kariuki 4. FEROZ ALI Allibhoy Site(s) in Kenya 1. Primecare Heart Clinic (Nairobi City county) 2. Dr. Silversteins Clinic (Nairobi City county) 3. Nairobi Cardiovascular Clinic (Nairobi City county) 4. Agah Khan Kisumu (Kisumu county) |
27-01-2015 |
View |
492. |
ECCT/14/11/02 | A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3 |
Principal Investigator(s) 1. VICTOR AKELO Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
02-02-2015 |
View |
493. |
ECCT/14/11/01 | ZEBOV Trial A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya. |
Principal Investigator(s) 1. Philip Bejon 2. Patricia Njuguna Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
08-12-2014 |
View |
494. |
ECCT/14/10/02 | Acronymn: CRASH-3 Short Title: Clinical Randomisation of an Antifibrinolytic in Significant Head Injury Full Title: Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial ISRCTN15088122 ClinicalTrials.gov ID: NCT01402882 |
Principal Investigator(s) 1. Kiboi Githinji Julius 2. Dullo Michael 3. Lallet Tasneem Essaji Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Kitui District Hospital (Kitui county) 3. The Nairobi Hospital (Nairobi City county) |
05-02-2015 |
View |
495. |
ECCT/14/10/01 | Evaluation of the AccuCirc for Early Infant Male Circumcision in Nyanza, Kenya |
Principal Investigator(s) 1. Rebeca Milanesi Plank 2. Robert Bailey Site(s) in Kenya Nyanza Reproductive Health Society |
15-01-2015 |
View |
496. |
ECCT/14/09/04 | Assessment of Safety and Efficacy of Brozedex Syrup in the Treatment of Productive Cough. Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel Group and Multi-Site Study Conducted In Nairobi in three sites |
Principal Investigator(s) 1. Hudson Aubrey Lodenyo Site(s) in Kenya 1. Rhodes Clinic/Ngaira Health Centre (Nairobi City county) 2. Mbagathi District Hospital (Nairobi City county) 3. Mama Lucy Hospital (Nairobi City county) |
09-12-2014 |
View |
497. |
ECCT/14/09/03 | Breast Feeding Study An open-label, short-duration, repeat-dose study of breast milk excretion and infant absorption of daily oral Tenofovir Disoproxil Fumarate/Emtricitabine when used by HIV-1 uninfected lactating women |
Principal Investigator(s) 1. Jared Murray Baeten 2. Nelly Rwamba Mugo Site(s) in Kenya Partners in Prevention, Thika Site |
19-08-2015 |
View |
498. |
ECCT/14/09/02 | LIVING STUDY-PHASE III B. Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study) |
Principal Investigator(s) 1. Elizabeth Maleche Obimbo 2. Elizabeth Bukusi 3. Winstone Nyandiko 4. Bienvenu Baruani Ngoy 5. Joseph Kariuki Mbuthia 6. Allan Godfrey Otieno 7. Lucy Koech 8. Neema Mturi 9. Beatrice Mutai Site(s) in Kenya 1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county) 2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county) 3. MSF Belgium Kibera Clinic (Nairobi City county) 4. Gertrude\'s Children\'s Hospital (Nairobi City county) 5. Mbagathi District Hospital (Nairobi City county) |
08-12-2014 |
View |
499. |
ECCT/14/09/01 | Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa. Study number: MALARIA-076 (200599) |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
23-09-2015 |
View |
500. |
ECCT/14/08/05 | Brief Bactericidal Activity of Anti TB drugs Brief Bactericidal Activity of Anti-Tuberculosis Drugs |
Principal Investigator(s) 1. Videlis Nzioka Nduba Site(s) in Kenya KEMRI-CGHR |
18-11-2014 |
View |